LUNDBECK Australia this morning
advised that the formulation of its
Ebixa (memantine hydrochloride)
10mg film-coated tablets will in
future be lactose-free.
The Alzheimer’s Disease
treatment will be available in the
new formulation from this month,
with the current lactose-containing
tablets to be discontinued.
According to the company, the
lactose-free tablets are pale yellow
and oval-shaped, in contrast to the
current lactose-containing product
which is white/off-white and
rectangular in shape.
There’s no change to the
formulation of Ebixa 20mg filmcoated
tablets, which are already
lactose-free.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Feb 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Feb 13
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.